SCHEMBL8217510

SCHEMBL8217510

CC1=C(C(=O)OCCO)[C@@H](c2ccc(CN)cc2)NC(=O)N1c1cccc(C(F)(F)F)c1

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 14/20 0.79
▸ CYP2C9 P11712 8/20 0.79
▸ ADRB1 P08588 1/20 0.51
▸ HTR1A P08908 1/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.51
▸ CYP2C8 P10632 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ CYP3A4 P08684 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8220267 0.92 ELANE (0.80) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL2894380 0.88 ELANE (1.00) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL3707890 0.88 ELANE (1.00) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL8050837 0.84 ELANE (0.79) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL8220629 0.83 ELANE (0.66) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL2888564 0.82 ELANE (0.79) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL9914387 0.82 ELANE (0.79) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL2887923 0.82 ELANE (0.79) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL13872092 0.81 ELANE (0.87) ELANECYP2C9ADRB1HTR1AHRH3
SCHEMBL14899925 0.81 ELANE (0.89) ELANECYP2C9ADRB1HTR1AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008003412-A1 THE USE OF 1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION BAYER HEALTHCARE AG (DE) 2008-01-10 — — WO disclosed
Send feedback